

Indraprastha Medical Corporation Limited

(Indraprastha Apollo Hospitals, New Delhi - A Joint Sector Venture of Govt. of Delhi)

Regd. Office : Sarita Vihar, Delhi-Mathura Road, New Delhi-110 076 (India)

Corporate Identity Number : L24232DL1988PLC030958

Phones : 91-11-26925858, 26925801, Fax : 91-11-26823629

E-mail : imcl@apollohospitals.com, Website : <https://delhi.apollohospitals.com>

Ref: IMCL/CS/BM/2023

4th August, 2023

The Manager
Listing Department
BSE Limited Phiroze Jeejeebhoy
Towers Dalal Street, Mumbai,
Maharashtra - 400001
Scrip Code: 532150

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra East,
Mumbai, Maharashtra - 400051
Symbol: INDRAMEDCO

Re: Outcome of the Board Meeting held on 4th August, 2023

Dear Sir,

This is to inform that the Board of Directors of the Company has, at its meeting held on Friday, 4th August, 2023 (i.e. today), inter-alia, considered and approved the following items:

1. **The Un-audited Financial Results of the company for the quarter ended 30th June, 2023.**

Considered and approved the Un-audited Financial Results for the quarter ended 30th June, 2023, along with the Limited Review Report of the statutory auditor.

2. **Change in Directorship - Resignation by Director**


Mr. Udit Prakash Rai (DIN - 07573658) - Non-Executive - Non-Independent Director, has resigned, due to his personal reasons, as a Director of the Company, w.e.f. 4th August, 2023.

3. **Convening Annual General Meeting**

Approved convening the thirty-fifth Annual General Meeting (AGM) of the Company, on Thursday, 21st September, 2023, through video conferencing / other audio visual means.

4. **Fixation of Record/Book Closure Dates**

The Register of Members and Share Transfer Books of the Company shall remain closed from Saturday, 16th September, 2023 to Thursday, 21st September, 2023 (both days inclusive) for the purpose of the AGM and declaration of dividend.



Indraprastha Medical Corporation Limited

(Indraprastha Apollo Hospitals, New Delhi - A Joint Sector Venture of Govt. of Delhi)

Regd. Office : Sarita Vihar, Delhi-Mathura Road, New Delhi-110 076 (India)

Corporate Identity Number : L24232DL1988PLC030958

Phones : 91-11-26925858, 26925801, Fax : 91-11-26823629

E-mail : imcl@apollohospitals.com, Website : <https://delhi.apollohospitals.com>

The Board meeting commenced at 3.00 p.m. and ended at 5:15 p.m.


We are enclosing herewith the Un-audited Financial Results for the quarter ended 30th June, 2023, along with a copy of the Limited Review Report by the Statutory Auditors of the Company.

This is for your information and record.

Thanking You,

Yours sincerely,

For Indraprastha Medical Corporation Limited



Priya Ranjan

AVP - Corporate Affairs & Legal
(Company Secretary & Compliance Officer)

Encl.: As above

Limited Review Report on Unaudited Quarterly Results**To the Board of Directors of Indraprastha Medical Corporation Limited**

1. We have reviewed the accompanying statement of unaudited financial results of Indraprastha Medical Corporation Limited ("the Company") for the quarter ended 30 June 2023 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India ("the SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 'Interim Financial Reporting' ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant Rules issued thereunder; and other accounting principles generally accepted in India. Our responsibility is to issue a conclusion on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S. N. Dhawan & CO LLP

Chartered Accountants

Firm Registration No.: 000050N/N500045

**Rajeev K Saxena**

Partner

Membership No.: 077974

UDIN No.: 23077974BGXFGH3260

Place: New Delhi

Date: August 04, 2023


Statement of unaudited Financial Results for the Quarter ended 30th June, 2023

S. No.	Particulars	Amount (Rs. in crore)			
		Quarter ended		Year ended	
		30.06.2023 (Unaudited)	31.03.2023 (Refer Note 3)	30.06.2022 (Unaudited)	31.03.2023 (Audited)
1	Revenue from operations	306.51	274.05	263.32	1098.67
2	Other Income	3.56	4.79	0.77	10.03
3	Total income	310.07	278.84	264.09	1108.70
4	Expenses				
	a) Cost of material consumed	54.18	47.28	49.67	193.61
	b) Employee benefits expense	63.27	65.38	55.04	246.70
	c) Professional charges to doctors	77.03	69.32	68.21	280.55
	d) Finance cost	0.78	0.87	1.15	4.28
	e) Depreciation and amortisation expense	9.81	9.86	9.70	39.27
	f) Other expenses	64.77	58.93	53.50	227.11
	Total expenses	269.84	251.64	237.27	991.52
5	Profit before exceptional items and tax	40.23	27.20	26.82	117.18
6	Exceptional items	-	-	-	-
7	Profit before tax (PBT)	40.23	27.20	26.82	117.18
8	Tax expense				
	Current tax	10.91	3.27	7.27	31.14
	Deferred tax	(1.18)	4.09	(0.73)	(0.11)
9	Profit for the period after tax (PAT)	30.50	19.84	20.28	86.15
10	Other comprehensive income				
	a). (i) Items that will not be reclassified to profit or loss	(0.46)	(7.76)	(0.30)	(12.32)
	(ii) Income Tax relating to items that will not be reclassified to profit or loss	0.12	1.95	0.08	3.10
	Total other comprehensive income (Net of tax expenses)	(0.34)	(5.81)	(0.22)	(9.22)
11	Total comprehensive income for the period	30.16	14.03	20.06	76.93
12	Paid-up equity share capital (Face value Rs. 10/- each)	91.67	91.67	91.67	91.67
13	Reserves (excluding Revaluation Reserves) as shown in the audited balance sheet of previous year				287.78
14	Earnings per share Basic and Diluted (Rs.) - Not Annualised	3.33	2.16	2.21	9.40

Notes:

1. The above financial results were reviewed by the Audit Committee and have been approved by the Board of Directors at their meeting held on 4th August, 2023.
2. The Company operates in a single segment i.e. Healthcare and hence, does not have any additional disclosures to be made under Ind AS 108 on Operating Segments.
3. The financial results for the three months ended 31st March, 2023 are the balancing figures between the audited figures for the year ended 31st March, 2023 and the unaudited year to date figures for the nine months ending 31st December, 2022, which were subject to limited review.
4. The Code on Social Security, 2020 has been enacted, which could impact the contributions by the company towards Provident Fund and Gratuity. The effective date from which the changes are applicable is yet to be notified. Impact if any, of the change will be assessed and accounted in period of notification of relevant provisions.
5. Previous year/period figures have been regrouped / rearranged wherever necessary.

Place : New Delhi
Date : 4th August, 2023


Shivakumar Pattabhiraman
(Managing Director)